

Evaluation of gonadotoxicity of cancer therapies to improve counselling of patients regarding fertility and fertility preservation measures: Protocol for a retrospective systematic data analysis and a prospective cohort study

Michael von Wolff, Ariane Germeyer, Bettina Böttcher, Isotta Martha Magaton, Irene Marcu, Janna Pape, Nicole Sängler, Verena Nordhoff, Marie Roumet, Susanna Weidlinger

Submitted to: JMIR Research Protocols
on: July 23, 2023

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript..... 5

Supplementary Files..... 25

 Figures 26

 Figure 1..... 27

 Figure 2..... 28

 Figure 3..... 29

 Multimedia Appendixes 30

 Multimedia Appendix 1..... 31

 Multimedia Appendix 2..... 31

 Multimedia Appendix 3..... 31

 Multimedia Appendix 4..... 31

Evaluation of gonadotoxicity of cancer therapies to improve counselling of patients regarding fertility and fertility preservation measures: Protocol for a retrospective systematic data analysis and a prospective cohort study

Michael von Wolff¹ MD; Ariane Germeyer² MD; Bettina Böttcher³ MD; Isotta Martha Magaton¹ MD; Irene Marcu¹ PhD; Janna Pape¹ MD; Nicole Sängler⁴ MD; Verena Nordhoff⁵ PhD; Marie Roumet⁶ PhD; Susanna Weidlinger¹ MD

¹University Women's Hospital, Division of Gynaecological Endocrinology and Reproductive Medicine, Bern, Switzerland Bern CH

²University Women's Hospital, Department of Gynaecological Endocrinology and Fertility Disorders, Heidelberg, Germany Heidelberg DE

³Department of Gynaecological Endocrinology and Reproductive Medicine, Medical University of Innsbruck, Austria Innsbruck AT

⁴University Women's Hospital, Department of Gynaecological Endocrinology and Reproductive Medicine, Bonn, Germany Bonn DE

⁵University of Münster, Centre of Reproductive Medicine and Andrology, Department of Clinical and Surgical Andrology, Münster, Germany Münster DE

⁶Clinical Trial Unit, University of Bern, Bern, Switzerland Bern CH

Corresponding Author:

Michael von Wolff MD

University Women's Hospital, Division of Gynaecological Endocrinology and Reproductive Medicine, Bern, Switzerland

Friedbuehlstrasse 19

Bern

CH

Abstract

Background: Cytotoxic treatments such as chemo- radio- and immune therapies are required in cancer diseases. These therapies may have an impact on gonadal function and therefore on fertility. Consequently, fertility preservation treatments such as freezing of oocytes, ovarian tissue, sperm and testicular tissue might be required. However, as detailed data about the necessity to perform fertility preservation treatment is very limited the following study was set up to fill this gap of data.

Objective: Primary objective of the study is to analyse the impact of cancer therapies and chemotherapies on the ovarian reserve (AMH concentration) and on sperm quality (sperm count and concentration). Secondary objectives are to analyse the impact of cancer therapies and chemotherapies on other fertility parameters and to analyse the probability of undergoing fertility preservation treatments in relation to specific cancer diseases and chemotherapy and treatment protocols.

Methods: First, previously published data will be systematically analysed regarding the gonadotoxicity of chemo- and radiotherapies in cancer patients.

Second, a prospective cohort study will be set up in Germany, Switzerland and Austria and the following data will be collected: evaluation of ovarian function by analysing AMH, FSH, LH and E2 concentrations and testicular function by analysing sperm parameters, total testosterone, FSH and LH concentration just before and around 1 year after gonadotoxic therapies (short-term fertility). A follow up of these fertility parameters including the history of potential conceptions will be performed 5 and 10 years after gonadotoxic therapies (long-term fertility). Additionally, the proportion of patients undergoing fertility preserving methods as well as their efficacy and their satisfaction with the used methods will be analysed.

Third, the data will be merged to create the internet-based data platform FertiTOX. The platform will be easily accessible using a specific App.

Results: By August 1st 2023 seven systematic reviews are in progress and the first systematic reviews has been submitted for publication. The prospective cohort study has just started. All Swiss and the leading ethics committees in Germany and in Austria have given their permission. 70 infertility centers have been prepared for data collection. The study registry has been set up and activated and a study website www.fertitox.ch has been uploaded. Recruitment of patients has started in August 2023 and first data will be expected to be uploaded on the Fertitox platform in 2026. Financing of the study is given by several founding bodies.

Conclusions: The study will fill the data gap on gonadotoxicity of previous and current chemotherapies and also provide data on the newly developed chemo- and immunotherapies. As the data will be presented online in a structured and comprehensive

manner, counseling patients on fertility issues will be greatly facilitated. Clinical Trial: ClinicalTrials.gov: NCT05885048.

(JMIR Preprints 23/07/2023:51145)

DOI: <https://doi.org/10.2196/preprints.51145>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ **Please make my preprint PDF available to anyone at any time (recommended).**

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in a JMIR publication, I will be able to make the full manuscript available to all users.

Original Manuscript

Evaluation of gonadotoxicity of cancer therapies to improve counselling of patients regarding fertility and fertility preservation measures: Protocol for a retrospective systematic data analysis and a prospective cohort study

Michael von Wolff^{1*}, Ariane Germeyer², Bettina Böttcher³, Isotta Magaton¹, Irene Marcu¹, Janna Pape¹, Nicole Sängler⁴, Verena Nordhoff⁵, Marie Roumet⁶, Susanna Weidlinger¹

¹University Women's Hospital, Division of Gynaecological Endocrinology and Reproductive Medicine, Bern, Switzerland

²University Women's Hospital, Department of Gynaecological Endocrinology and Fertility Disorders, Heidelberg, Germany

³Department of Gynaecological Endocrinology and Reproductive Medicine, Medical University of Innsbruck, Austria

⁴University Women's Hospital, Department of Gynaecological Endocrinology and Reproductive Medicine, Bonn, Germany

⁵University of Münster, Centre of Reproductive Medicine and Andrology, Department of Clinical and Surgical Andrology, Münster, Germany

⁶Clinical Trial Unit, University of Bern, Bern, Switzerland

***Corresponding author:**

Prof. Dr. med. Michael von Wolff

University Women's Hospital, University of Berne, Switzerland.

E-Mail: Michael.vonwolff@insel.ch

Abstract

Background

Cytotoxic treatments such as chemo- and radiotherapy and immune therapies are required in cancer diseases. These therapies have the potential to cure patients, but may also have an impact on gonadal function and therefore on fertility. Consequently, fertility preservation treatments such as freezing of gametes and gonadal tissue might be required. However, as detailed data about the necessity to perform fertility preservation treatment is very limited the following study was set up

to fill this gap of data.

Objectives

Primary objective of the study is to analyse the impact of cancer therapies and chemotherapies on ovarian reserve and on sperm quality. Secondary objectives are to analyse the impact of cancer therapies and chemotherapies on other fertility parameters and to analyse the probability of undergoing fertility preservation treatments in relation to specific cancer diseases and treatment protocol and the probability to use the frozen gametes and gonadal tissue to achieve pregnancies.

Methods

The following methods will be involved:

First, previously published studies are systematically analysed regarding the gonadotoxicity of chemo- and radiotherapies in cancer patients.

Second, a prospective cohort study has been set up by approximately 70 centres in Germany, Switzerland and Austria and the following data will be collected: evaluation of ovarian function by analysing AMH concentrations and testicular function by analysing sperm parameters and total testosterone just before and around 1 year after gonadotoxic therapies (short-term fertility). A follow up of these fertility parameters including the history of conceptions will be performed 5 and 10 years after gonadotoxic therapies (long-term fertility). Additionally, the proportion of patients undergoing fertility preserving methods, the satisfaction with the methods and the amount of gametes and gonadal tissue and the children achieved by using the frozen material will be analysed. Third, the data will be merged to create the internet-based data platform FertiTOX®. The platform will be structured according to the ICD classification of cancer diseases and will be easily be accessible using a specific App.

Results

Financing of the study is given by several founding bodies. Six systematic reviews are in progress and the first systematic review has been submitted for publication. All Swiss and many ethics committees in Germany and Austria have given their permission for the prospective cohort study. The study registry has been set up and a study website www.fertitox.ch has been uploaded. 40 infertility centers have already been prepared for data collection which has started December 1st 2023.

Conclusions

The study can be expected to fill the data gap of the gonadotoxicity of cancer therapies to better

counsel patients regarding their infertility risk and their need of perform fertility preservation measures. First data will be expected to be uploaded on the FertiTOX® platform in 2026.

The trial was registered at ClinicalTrials.gov: NCT05885048.

Background

After reaching milestones in fertility preservation such as freezing of sperm and testicular tissue and more recently the first birth after transplantation of cryo-preserved ovarian tissue [1], the introduction of luteal phase and thereby random start gonadotropin stimulation [2] and vitrification of oocytes [3], fertility preservation treatments have been introduced in most countries and fertility preservation has been accepted and defined as an important element to be considered before cancer treatments (Figure 1).

Medically this has been shown by several national and international guidelines stating that fertility preservation counselling is required before gonadotoxic therapies [4-11] and politically it has been shown as many countries have introduced reimbursement / coverage of fertility preservation treatments.

However, data about the gonadotoxicity of the numerous cancer treatment regimes are mostly very limited. Additionally, a recent study in mice has revealed that immune therapies such as checkpoint inhibitors have substantial impact on ovarian reserve [12], but human data is not yet available.

Accordingly, indications for or against fertility preserving therapies are not well defined with either the risk of over-treating patients with therapies, imposing unnecessary medical risks and burdens to the patients and therefore unnecessarily postponing the gonadotoxic therapies. On the other hand, the risk of under-treating patients with respective therapies imposes the risk of infertility, which can have a substantial impact on quality of life after cancer [13].

Meanwhile effective methods are available to reliably quantify the gonadotoxicity of cancer therapies. In females, ovarian function can be evaluated by analysing AMH, FSH, LH and E2 concentrations, and in males testicular function is evaluated by analysing sperm counts as well as total testosterone, FSH and LH concentrations.

Even though these functional parameters exist, prospective and systematic short and long term data

of the impact of specific cancer therapies on fertility based on these parameters are limited. It can be assumed that this is due to a lack of effective fertility preservation network structures in most countries. However, in Switzerland, Germany and Austria such network structures have been established which permit a systematic and continuous large-scale data analysis.

Data should be made available as an easily accessible internet platform which is merged with already published data on the gonadotoxicity of cancer therapies and other relevant data such as the 5-year survival rates of the cancer diseases. The data platform will support physicians and other experts and also patients in counselling about fertility risks imposed by cancer treatments and the necessity to undergo fertility preserving measures.

We therefore set up a study to collect data on the gonadotoxicity of cancer therapies by systematically analysing already published data and by setting up an international multicentre prospective cohort study to collect data in females and males on the gonadotoxicity of chemotherapies, radiotherapies and immune therapies and to upload summarized data on an internet based data platform.

Objectives

The primary objective is to analyse if cancer therapies and specific chemotherapy protocols reduce AMH concentration in females and sperm quality.

Secondary objectives are to analyse the impact of cancer therapies and chemotherapies on other fertility parameters such as the probability of undergoing fertility preservation treatments in relation to the type of cancer disease and specific treatment protocols, the number of children, the future wish to have children and age. Further objectives are to assess satisfaction with the decision to have undergone fertility preservation measures or not, the proportion of females and males who use their frozen gametes to achieve a pregnancy, the effect of different gonadotoxic therapies on long-term fertility and to analyse life quality after cancer therapies.

Methods

Study design

The study consist of two parts: First, a series of systematic reviews. Second, an international multicentre prospective exploratory observational cohort study of fertility related parameters with a long-term follow-up of cancer patients` fertility in university and non-university public hospitals and

private infertility centres in Germany, Switzerland and Austria. All data will be uploaded on an internet-based data platform.

First part: Retrospective systematic data analysis

A series of systematic reviews is performed in Switzerland. The reviews cover diseases for which a sufficient number of studies has been published to perform a systematic review and which are relevant regarding fertility and fertility preservation issues. The following reviews have been started in 2023 or are expected to be published in 2024 and 2025. They are registered at PROSPERO (www.crd.york.ac.uk/prospero/):

- A systematic review of the gonadotoxicity of Osteosarcoma and Ewing's sarcoma chemotherapies in postpubertal females and males: CRD42023331654, submitted for publication in 2023.
- Effects of chemotherapy and radiation in mesothelial and soft tissue cancer on ovarian and testicular function and fertility: CRD42023385402, to be submitted for publication in 2024.
- Effects of chemotherapy and radiation in male genital organ tumors on ovarian and testicular function and fertility: CRD42023384057, to be submitted for publication in 2024.
- Effects of chemotherapy, radiation and immunotherapy in breast cancer on ovarian and testicular function and fertility: CRD42023384042, to be submitted for publication in 2024.
- Effects of bone marrow transplantation in hematological tumors on ovarian and testicular function and fertility: CRD42023486928, to be submitted for publication in 2024.
- Effects of chemotherapy and radiation in eye, brain and central nervous system cancer on ovarian and testicular function and fertility: CRD42023385408, to be submitted for publication in 2025.
- Effects of chemotherapy and radiation in Hodgkin lymphoma on ovarian and testicular function and fertility: CRD42023384052, to be submitted for publication in 2025.

Second part: Prospective cohort study

The cohort study will collect ovarian reserve and sperm data from patients undergoing gonadotoxic therapies. Data collection was started December 1st 2023 and will be continued at least for 5 years to analyse short-term fertility. Long-term fertility data will be collected until at least 2036. A first version of the FertiTOX internet platform is expected to be set up in 2026. The trial is registered at ClinicalTrials.gov: NCT05885048.

Inclusion criteria

Each centre that counsels cancer patients regarding fertility issues and that can also provide fertility associated parameters may participate. Prerequisite requirement is that each centre has received ethical approval for the study. Even though the study is intended to mainly include FertiPROTEKT network centres (www.fertiprotekt.com) and FERTISAVE (www.sgrm.org/de/kommissionen/fertisave-main-de) networks in Germany, Switzerland and Austria, any other centre worldwide can participate if the inclusion criteria are fulfilled.

Females and males at the age of 14-50 years (Germany 18-50 years due to national regulations) undergoing cancer therapies using chemotherapy, radiotherapy or immune therapy (Figure 1) will be included.

Recruitment and informed consent procedure

Patients are recruited by reproductive physicians who are associated to participating infertility centres. Approximately 70 centres (Germany 44 centres, Switzerland 21 centres and Austria 6 centres) will participate in the study and will collect data (see Supplement I).

Patients who need gonadotoxic therapies are counselled before the onset of the respective therapies. During the counselling, patients are screened for eligibility to be included in the study.

Furthermore, patients receive counselling sheets to give informed consent before the onset of the gonadotoxic therapy to collect patients' specific basic data and data on gonadal function. Data will also be collected 12-15 months and 5 and 10 years after the end of gonadotoxic therapy.

The project participants are informed that they will be contacted by the fertility centre or a defined co-worker of the study by telephone, e-mail or by mail to collect the respective data after the gonadotoxic therapy. Participants are informed that they will not receive any compensation.

Study registry

Data will be collected using the RedCap software, a secure web application for building databases (www.project-redcap.org). The RedCap registry has been set up and optimized by the study consortium with the support of the Clinical Trials Unit in Bern, RedCap technicians and statisticians. The contents of the study registry (consultation before and 12-15 months after the end of the gonadotoxic therapy) are shown in the paper version of the registry (Supplements II-V). The participating centers will add the data to the registry without adding any definite identifiers such as

name and date of birth. The participating centers can only see their patients. Patients can be traced with an individual code which is kept safely by the centers. Only very few authorized persons will get access to all data in order to check the data quality and to remind the centers to invite the patients for follow up consultations.

Endpoints

Primary endpoints are the concentration of Anti mullerian hormone (AMH) in females and concentration of sperm before and after gonadotoxic treatments. Endpoints will be assessed before and 12-15 months after the end of the gonadotoxic treatments (melanoma patients receiving adjuvant checkpoint inhibitor treatment will be evaluated every 3 months).

Secondary endpoints are Follicle stimulating hormone (FSH), Luteinizing hormone (LH) and Estradiol (E2) concentration in females and total testosterone, FSH and LH concentration, total sperm count and sperm motility in males. Further secondary outcome parameters are the number of patients who freeze gametes and gonadal tissue and satisfaction with the decision to have undergone fertility preservation measures or not.

Long-term endpoints to be determined 5 and 10 years after the end of the gonadotoxic therapy are the above mentioned hormone and sperm parameters as well as the number of patients who become pregnant after gonadotoxic therapies spontaneously or after use of frozen gametes and gonadal tissue.

Sample size calculation

A power calculation was performed to assess whether the expected number of patients is sufficient to detect an effect of cancer treatment on fertility with a reasonable power.

The calculation was performed for the primary outcome (i.e., sperm concentration for males and AMH for females) for males and females separately. Calculations were performed within each cancer entity and for each specific treatment protocol separately based on a paired t- test, using Stata (Release 17.0).

We set the effect size so that a relative risk of 50% was not missed. For the sperm count where the mean value in healthy men is 64 million with a standard deviation (SD) of 47 [14], this would correspond to an effect size of 0.67. For female AMH concentration where means and standard deviations (SD) can be assumed to be equal [15], it would correspond to an effect size of 0.5. The

intraindividual correlation was set to 0.5 [14, 15]. To account for multiple testing (analysis will be performed in 43 treatment groups for males and females separately), the Šidák correction was used and the significance level adjusted to 0.0006 (two sided).

Table 1

Expected number of cases and resulting power reached per specific treatments (treatment protocols) in the most common ICD cancer groups (www.krebsdaten.de/Krebs/DE/Home/homepage_node.html).

ICD cancer group	Cases, n *	Specific treatments (treatment protocols), n	Effect size (females/males)**	Power, % (females/males)**
Breast	2000	6	0.5/ -	100/ -
Hodgkin's lymphoma	1000	2	0.5/0.68	100/100
Bone and articular cartilage	400	3	0.5/0.68	98.6/100
Female genital organs	350	3	0.5/ -	96.5/ -
Male genital organs	2000	4	-/0.68	-/100
Digestive organs	200	7	0.5/0.68	14.3/41.4
Mesothelial and soft tissue	200	3	0.5/0.68	67.2/96.7
Eye, brain & central nervous system	300	2	0.5/0.68	99.5/100
Non-Hodgkin's lymphoma	300	8	0.5/0.68	26.2/64.4
Leukaemia	200	5	0.5/0.68	30.6/70.8

* The estimation of the number of cases is based on the number of cases previously counselled and documented in the *FertiPROTEKT* and *FERTISAVE* registries.

**Power is calculated for each treatment protocol, for males and females separately. The number of patients per protocol is calculated as the number of cases divided by the number of treatment protocols. The sex ratio is assumed to be 1:1 except for cancer of breast and genital organs.

Table 1 reveals that sufficient power of > 80% will be reached for most treatments.

If the number of cases were twice as high and the intra-patient correlation was 0.7, power > 80% would be reached for all treatment levels. As the study is expected to be extended a sufficient number of patients to reach this goal can be expected.

Data analysis

The impact of cancer therapies and chemotherapies on the primary outcomes will be assessed for each ICD cancer group (www.krebsdaten.de/Krebs/DE/Home/homepage_node.html) and for each specific treatment regimes separately, by comparing values measured before and after the gonadotoxic therapy using paired t-tests. P-values will be adjusted for multiple testing using the false discovery rate (FDR) controlling procedure. Consequences on other fertility parameters measured before and 12-15 months after the end of gonadotoxic therapy (i.e., females: AMH, FSH, LH and E2 concentration, males: total testosterone, FSH and LH concentrations and total sperm count, sperm concentration and motility), will be assessed using the same methodology, but without FDR adjustment. Long-term consequences will be investigated later, by comparing values measured before and 5 years and 10 years after the gonadotoxic therapy. However, due to the long period until the final analysis, statistics might be adapted in relation to future development of cancer and the fertility preservation therapies.

As age was identified to potentially modify the effect of gonadotoxic therapy on female fertility, we will additionally conduct stratified analyses and document the impact of gonadotoxic therapy in the different female age groups.

Finally, the effects of different cancers, the treatment protocol, age, and the presence of own children before cancer therapy on primary and secondary fertility outcomes will be analysed using linear mixed effect models.

The frequency of patients undergoing fertility preservation treatments, namely freezing of ovarian tissue, oocytes and embryos, testicular tissue and sperm will be calculated for each ICD cancer group and for each specific treatment protocol separately and additionally presented with the associated 95% Wilson confidence interval. Potential effects of the patients' characteristics on the binary outcomes mentioned above will be analysed using logistic regression.

Consortium of experts involved in the study

The project is supervised by several experts in Germany, Switzerland and Austria (Figure 2). Each country provides the logistics, manpower and experts to collect and control data collection and analysis. Interpretation of data will be supported by oncologists. Data are added to a RedCap study registry, which is provided by the Clinical Trial Unit Bern, Switzerland which is also responsible for statistical analysis. The data platform will be programmed by an IT company and data presentation will be optimized by the involved experts and by patients' representatives. The data platform called FertiTOX® will be part of the network FertiPROTEKT.

FertiTOX® platform

The FertiTOX® platform is an internet-based information platform that will be accessible for everybody and will be structured based on the ICD cancer disease groups (Figure 3). The brand name FertiTOX® has been registered and the domains www.fertitox.com/de/ch/at/ will be used. A study website (www.fertitox.com) has been set up.

Data of females and males will be presented on the FertiTOX® platform in 3 hierarchies:

- 1st hierarchy: Presentation of data regarding incidences and 5 years survival per ICD classified cancer diseases.
- 2nd hierarchy: Presentation of already published data regarding gonadotoxicity and fertility preservation issues regarding specific ICD classified diseases.
- 3rd hierarchy: Presentation of prospective short term and long-term data on ovarian reserve and sperm quality before and after gonadotoxic therapies per ICD classified diseases.

Once the internet platform is successfully established, a platform-specific App will be developed to allow easy retrieval of data.

Dissemination

Data about the progress of the study will be disseminated through a study website www.fertitox.com. The findings will be propagated through journal articles, conference presentations and the platform FertiTOX®.

Ethics considerations

Ethical approval is granted by the relevant ethical committees. In Switzerland all seven cantonal ethical committees have given consent for all 21 participating centers. In Germany the ethical committee in Heidelberg and in Austria the committee in Innsbruck were chosen as national leading ethical committees. Based on the ethical votes approved by these two committees all other participating centers in Germany and Austria submitted an ethical application to their ethical committee.

Written consent is given by the participants. The participants are informed about the processing of data and their rights. The participants also give written consent that anonymized data can be transferred to other registries for further analysis if the other registry have the same high security standards as the RedCap registry. The data are collected in a RedCap study registry that complies with several data security and confidentiality conditions. Specific identifiers are not added to the registry, only the year of birth. The data are stored in Bern, Switzerland.

The participating centers can only access the patient's data they have been added to the registry.

The patients can be identified by an individual code, generated by the RedCap system, which is locked in a safe place by the investigator of the participating center. Traceability of the data is ensured by these identification codes. Patients give permission to be followed up. Patients are only contacted by the center or by authorized personal employed by the principal investigator or the national representatives of the study. Statistical analysis will be based on anonymized data.

No compensation will be offered to users for participating in the study.

Results

By December 1st 2023 the following achievements have been made:

The first systematic review, analysing the impact of cancer therapies on bone tumours has been submitted for publication. Five more systematic reviews have been initiated. They are covering the impact of cancer therapies on fertility in breast cancer, testicular cancer, hodgkins lymphoma, soft tissue cancer and the impact of bone marrow transplantation.

The prospective cohort study has been prepared. All Swiss ethics committees and the leading ethics committees in Germany and in Austria have given their permission. 70 infertility centers (Supplement I) have been prepared for data collection. The study registry has been set up and activated and a study website www.fertitox.ch has been completed.

Financing of the study is given by several funding bodies such as Swiss cancer league (Grant number KLS-5650-08-2022: CHF 349.000,-) and pharmaceutical companies such as IBSA Institut Biochimique SA, Theramex Switzerland GmbH and Ferring AG Switzerland. Pharmaceutical companies are not involved in any issues regarding the study concept, the analysis and the dissemination of data. A grant application has been submitted to the German “Krebshilfe”.

Recruitment of patients has started December 1st 2023 and first data will be expected to be uploaded on the Fertitox platform in 2026.

Discussion

The systematic reviews which we have already been prepared revealed that data on the impact of gonadotoxic therapies on fertility is quite comprehensive in some diseases such as breast and testicular cancer and hodgkin’s lymphoma. For these diseases a meta-analysis will also be set up to analyse the overall effect of oncological therapies on fertility. Furthermore, for these diseases the gonadotoxic effect of specific chemotherapy protocols on fertility will also be assessed. For the other diseases data are very poor and outcome parameter need to be limited to a rather vague outcome

parameter defined as “suspected infertility”. Long term fertility data based on ovarian reserve and sperm parameters and on spontaneous conceptions and conceptions using cryopreserved gametes or gonadal tissues are very poor or not existent in all kind of cancers.

This finding supports the necessity to perform the large prospective cohort study as described in this manuscript. This cohort study has already successfully been set up and data collection has been started December 1st 2023.

Solid data on the gonadotoxicity of different treatment regimes, mainly in cancer therapies, is the last major deficit in fertility preservation. All other requirements have been established in many countries such as fertility preservation measures and specialized centers to counsel patients and to perform these measures. Furthermore, many oncologists have been sensitized to address the fertility risk of cancer therapies and the possibility to perform fertility preservation measures.

However, what is still missing are comprehensive data about the specific gonadotoxicity of different treatment regimes which are required to counsel patients and to decide if fertility preservation measures should be recommended or not.

Previous studies have addressed fertility issues in cancer patients and the impact of cancer therapies on fertility but these studies are mostly based on spontaneous pregnancies following cancer therapies or are based on data such as the onset of puberty, cycle regularity and on few sperm counts. Studies based on pre- and post-chemotherapy treatment levels of AMH concentration and sperm counts are very limited and mainly limited to female breast cancer patients [16-19].

To close this data gap we set up a study in which we analyse data which have already been published and data which will be collected in at least three countries by centers belonging to the network FertiPROTEKT. The data will be analysed und disseminated via a web based platform called FertiTOX® to give patients, researchers and clinicians access to the analysis which will graphically illustrated. By including patient`s representatives in the data analysis we will ensure that the data will be presented in a way which is also understandable for patients. The data will not only be presented as a single curve presenting the means and showing odd ratios and confidence intervals which presents an average impact of therapies on gonadal function but will also show individual variations by presenting a set of curves.

The study has been designed to follow up patients for at least 10 years. Such a long follow up will enable us to evaluate how many patients have undergone fertility preservation measures but unfortunately did not survive. Furthermore, we will be able to estimate how many patients conceived spontaneously or by using the frozen gametes and gonadal tissue. Such an analysis is essential to evaluate the long term efficacy of fertility preservation counselling and treatment. We are aware that

some patients might be lost from the follow up process. But as the number of included patients is expected to be very high it can be assumed that the amount of data will still be sufficiently high.

The limitation of the study is that data are mainly collected in Germany, Switzerland and Austria. Accordingly, data will not be available for other treatment regimes which are performed elsewhere. However, as other countries are also invited to participate to join this study this limitation could possibly be reduced.

Another limiting factor is that children will not be evaluated. The main reason is that the study is based on AMH values and sperm parameters which can hardly be interpreted in children (AMH) or cannot be collected (sperm).

The last limiting factor is that new therapies are evolving very fast and that new combination therapies combining conventional chemotherapy agents and immune therapies will be developed which will increase the complexity of our data analysis. However, it is expected that this limitation can at least in part be compensated by the prospective design of the study which will include a higher number of new therapies. Furthermore, as checkpoint inhibitors which have been shown to be gonadotoxic in female mice will be analysed separately in women undergoing adjuvant therapy with checkpoint inhibitors for melanoma. These study results can be used to better estimate the gonadotoxicity of combination therapies involving checkpoint inhibitors.

In conclusion,

the study can be expected to fill the data gap of the gonadotoxicity of several therapies and gonadotoxic treatment regimes to better counsel patients regarding their infertility risk and their need of perform fertility preservation measures.

Acknowledgements

We would like to thank all participating centers for their support in preparing this study and collecting data.

Competing interests

No competing interests regarding the study.

Data availability

Participants have given written consent that data can also be analysed by others if sufficient data safety can be confirmed. Accordingly data can be considered by the study consortium to be transferred to others if sufficient data safety has been proven.

References

- 1 Donnez J, Dolmans MM, Demylle D et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. *Lancet*. 2004;364:1405-10.
- 3 Cobo A, Meseguer M, Remohí, J et al. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. *Hum Reprod*. 2010;25:2239-46.
- 2 von Wolff M, Thaler CJ, Frambach T et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. *Fertil Steril*. 2009;92:1360-5.
- 4 Loren AW, Mangu PB, Nohr Beck L et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* 2013;31: 2500-10.
- 5 AWMF. German, Austrian, Swiss guideline "Fertilitätsprotektion bei onkologischen Erkrankungen", 2017. Valid until September 30th, 30.09.2022. https://www.awmf.org/uploads/tx_szleitlinien/015-082l_S2k_Fertilitaetserhaltung-bei-onkologischen-Therapien_2017-12-verlaengert.pdf. Last access: April 23rd 2023.
- 6 Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. *Fertil Steril*. 2019;112:1022-1033.
- 7 ESHRE Guideline Group on Female Fertility Preservation, Anderson RA et al. ESHRE guideline: female fertility preservation. *Hum Reprod Open*. 2020;2020:hoaa052.
- 8 Suzuki N. Clinical Practice Guidelines for Fertility Preservation in Pediatric, Adolescent, and Young Adults with Cancer. *International journal of clinical oncology* 2019;24: 20-7.
- 9 Harada M, Kimura F, Takai Y et al. Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1. *International journal of clinical oncology* 2022;27: 265-80.
- 10 Mulder RL, Font-Gonzalez A, Green DM et al. Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol*. 2021;22:e57-e67.
- 11: Mulder RL, Font-Gonzalez A, Hudson MM et al. Fertility preservation for female patients with

- childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol.* 2021;22:e45-e56.
- 12 Winship AL, Alesi LR, Sant S et al. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. *Nat Cancer.* 2022;3:1-13.
- 13 Ussher JM, Perz J. Infertility-related distress following cancer for women and men: A mixed method study. *Psychooncology.* 2019 Mar;28:607-14.
- 14 Cooper TG, Noonan E, von Eckardstein S et al. World Health Organization reference values for human semen characteristics. *Hum Reprod Update.* 2010;16:231-45.
- 15 Segawa T, Omi K, Watanabe Y et al. Age-specific values of Access anti-Müllerian hormone immunoassay carried out on Japanese patients with infertility: a retrospective large-scale study. *BMC Womens Health.* 2019;19:57.
- 16 Dezellus A, Barriere P, Campone M, Lemanski C, Vanlemmens L, Mignot L, Delozier T, Levy C, Bendavid C, Debled M, Bachelot T, Jouannaud C, Loustalot C, Mouret-Reynier MA, Gallais-Umbert A, Masson D, Freour T. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. *Eur J Cancer.* 2017;79:72-80.
- 17 Perdrix A, Saint-Ghislain M, Degremont M, David M, Khaznadar Z, Loeb A, Leheurtur M, Di Fiore F, Clatot F. Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer. *Reprod Biomed Online.* 2017;35:468-474.
- 18 Trapp E, Steidl J, Rack B, Kupka MS, Andergassen U, Jückstock J, Kurt A, Vilsmaier T, de Gregorio A, de Gregorio N, Tzschaschel M, Lato C, Polasik A, Tesch H, Schneeweiss A, Beckmann MW, Fasching PA, Janni W, Müller V. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study. *Breast.* 2017 Oct;35:130-135.
- 19 Zhou B, Kwan B, Desai MJ, Nalawade V, Ruddy KJ, Nathan PC, Henk HJ, Murphy JD, Whitcomb BW, Su HI. Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors. *Fertil Steril.* 2022;117:1047-1056.

Figures

Figure 1

Algorithm for indicating fertility preserving therapies in females and males (adapted from von Wolff

& Nawroth, 12).

Figure 2

The consortium of experts which control the project

Figure 3

The internet platform FertiTOX which will be used to distribute the data

Supplement I

Centers participating the prospective cohort study (in alphabetical order)

Supplement II

RedCap registry: Documentation in females before gonadotoxic therapy

Supplement III

RedCap registry: Documentation in males before gonadotoxic therapy

Supplement IV

RedCap registry: Documentation in females 12-15 months after the end of gonadotoxic therapy

Supplement V

RedCap registry: Documentation in males 12-15 months after the end of gonadotoxic therapy

Supplement I

Centers participating the prospective cohort study (in alphabetical order)

Germany

- Aachen: Universitätsklinikum RWTH Aachen, Frauenklinik für Gynäkologische Endokrinologie und Reproduktionsmedizin - Dr. med. Nele Freerksen-Kirschner
- Berlin: Charité Universitätsmedizin Berlin, Charité, Centrum für Frauen-, Kinder- und Jugendmedizin mit Perinatalzentrum und Humangenetik, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie - Prof. Dr. med. Jalid Sehouli, Dr. med. Judith Altmann
- Berlin: Fertility Center Berlin - Prof. Dr. med. Heribert Kentenich, Dr. med. Andreas Tandler-Schneider
- Berlin: Kinderwunschzentrum an der Gedächtniskirche Berlin - Dr. med. Matthias Bloechle, Dr. med. Silke Marr
- Bielefeld: Bielefeld Fertility Center - Dr. med. Karl Völklein
- Bonn: Universitätsklinikum Bonn, Venuskind am UKB, Kinderwunschzentrum - Prof. Dr. med. Nicole Sänger, Dr. med. Julia John
- Bremen: Klinikum Bremen Mitte, Klinik für Gynäkologie - Dr. med. Mustafa Aydogdu
- Dortmund: MVZ Kinderwunschzentrum Dortmund GmbH - Prof. Dr. med. Stefan Dieterle
- Dresden: Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe - Dr. med. Maren Goeckenjan-Festag

- Düsseldorf: Universitätsklinikum Düsseldorf, UniKid Universitäres Interdisziplinäres Kinderwunschzentrum Düsseldorf - Prof. Dr. med. Jan-Steffen Krüssel
- Erlangen: Uniklinikum Erlangen, Frauenklinik - Prof. Dr. rer. nat. Ralf Dittrich
- Frankfurt: Re-Pro Gyn Universitätsklinikum Frankfurt - Dr. med. Rahila Nuriyeva, Dr. med. Aynura Abbasova-Semiz
- Freiburg: Universitätsklinikum Freiburg, Klinik für Frauenheilkunde - Dr. med. Philipp Wiehle, Dr. med. Jasmin Asberger
- Gießen: UKGM Universitätsklinikum Gießen und Marburg GmbH, Standort Gießen, Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie - Prof. Dr. med. Hans-Christian Schuppe, Prof. Dr. med. Adrian Pilatz, Prof. Dr. med. Florian Wagenlehner
- Gießen: UKGM Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Klinik für Frauenheilkunde und Geburtshilfe - Prof. (apl.) Dr. med. Volker Ziller
- Göttingen: UMG Universitätsmedizin Göttingen, Klinik für Gynäkologie und Geburtshilfe - Priv.-Doz. Dr. Dr. Gerd Bauerschmitz
- Greifswald: Universitätsmedizin Greifswald, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe - Prof. Dr. med. Marek Zygmunt
- Halle: Universitätsklinikum Halle (Saale), Zentrum für Reproduktionsmedizin und Andrologie (ZRA) - Prof. Dr. med. Hermann M. Behre
- Hamburg: amedes experts hamburg Facharzt-Zentrum für Kinderwunsch, Pränatale Medizin, Endokrinologie und Osteologie - Prof. Dr. med. Frank Nawroth
- Hannover: MHH Medizinische Hochschule Hannover, Klinik für Frauenheilkunde und Geburtshilfe - Prof. Dr. med. Cordula Schippert, Prof. Dr. med. Frauke von Versen-Höyneck
- Heidelberg: Universitätsklinikum Heidelberg - Prof. Dr. med. Ariane Germeyer
- Heidelberg: Universitätsklinikum Heidelberg, National Center for Tumor Diseases (NCT) Heidelberg - Prof. Dr. med. Carsten Müller-Tidow und Prof. Dr. med. Andreas Schneeweiss
- Hildesheim: Zentrum für Reproduktionsmedizin und Humangenetik Hildesheim - Dr. med. Jan-Simon Lanowski
- Karlsruhe: Städtisches Klinikum Karlsruhe, Frauenklinik - Prof. Dr. med. Andreas Müller
- Kassel: MVZ Medizinisches Versorgungszentrum für Reproduktionsmedizin am Klinikum Kassel - Dr. med. Marc Janos Willi, Dr. med. Oswald Schmidt
- Kiel: Universitäres Kinderwunschzentrum Kiel Lübeck Manhagen - Priv.-Doz. Dr. med. Sören von Otte
- Köln: MVZ PAN-Institut Köln - Dr. Irene Pütz
- Köln: Klinikum der Universität zu Köln (AöR), Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe - Prof. Dr. med. Gohar Rahimi
- Leipzig: Universitätsklinikum Leipzig, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie - Prof. Dr. med. Sonja Grunewald
- Lübeck: Universitätsklinikum Schleswig-Holstein, Sektion für gynäkologische Endokrinologie und Reproduktionsmedizin - Prof. Dr. med. Georg Griesinger
- Magdeburg: Universitätsklinikum Magdeburg A.ö.R., Universitätsklinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin - Dr. med. Carina Strecker
- Mainz: Universitätsmedizin Mainz, Universitäts-Kinderwunschzentrum und Ambulanz für Gynäkologische Endokrinologie und Reproduktionsmedizin - Prof. Dr. med. Christine Skala, Dr. med. Susanne Theis
- München: Kinderwunschzentrum A.R.T. Bogenhausen - Dr. med. Stephanie Ziehr
- München: LMU Klinikum der Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU Hormon- und Kinderwunschzentrum - Prof. Dr. med. Christian J.

Thaler, Prof. Dr. med. Nina Rogenhofer

- München: TUM Klinikum rechts der Isar, Technische Universität München, Klinik und Poliklinik für Frauenheilkunde - Prof. Dr. med. Vanadin Seifert-Klauss, Prof. Dr. med. Marion Kiechle
- Münster: UKM Universitätsklinikum, Münster Kinderwunschzentrum - Prof. Dr. med. Hermann M. Behre
- Münster: UKM Universitätsklinikum, Münster Centrum für Reproduktionsmedizin und Andrologie - Priv. Doz. Dr. rer. nat. Verena Nordhoff, Prof. Dr. rer. nat. Stefan Schlatt, Prof. Dr. med. Sabine Kliesch
- Oldenburg: Tagesklinik Oldenburg - Dr. med. Jörg Hennefründ (Dipl. Biologin Gabriele Remek)
- Regensburg: Profertilita Zentrum für Fruchtbarkeitsmedizin - Dr. med. Karla Gisch-Pratsch, Dr. med. Christine Reißmann
- Rostock: Praxiszentrum Frauenheilkunde - Priv. Doz. Dr. med. Heiner Müller, Dr. med. Anne Koenen
- Saarland: Universitätsklinikum des Saarlandes, Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin Homburg/ Saar - Dr. Simona Baus
- Tübingen: Universitäts-Frauenklinik, Department für Frauengesundheit Tübingen - PD Dr. med. Melanie Henes
- Ulm: Universitätsklinikum Ulm Klinik für Frauenheilkunde und Geburtshilfe, Kinderwunsch- und Hormonzentrum UniFee - Prof. Dr. med. Katharina Hancke
- Wiesbaden: MVZ TFP Rhein-Main GmbH, TFP Kinderwunsch Wiesbaden - Dr. med. Karin Schilberz
- Würzburg: Universitätsklinikum Würzburg, Zentrum für gynäkologische Endokrinologie und Reproduktionsmedizin - Dr. med. Michael Schwab

Switzerland

- Baden-Dättwil: Baden Täfernhof - Dr. med. Mischa Schneider
- Basel: Regio Basel - Dr. med. Erika Ocon
- Basel: Universitätsspital Basel - Dr. med. Ursula Gobrecht-Keller
- Bern: Inselspital - Prof. Dr. med. Michael von Wolff
- Bern: Lindenhofspital - Dr. med. Elisabeth Berger-Menz
- Biel: CARE - Dr. med. Susanna Crazzolara
- Chur: Kantonsspital Graubünden, Fontana - Dr. med. Naomi Ventura
- Fribourg: HFR - PD Dr. med. Dorothea Wunder
- Genève: HUG - Dr. med. Federico Del Vento
- Küsnacht: GYNE INVITRO - Dr. med. Michael Singer
- Lausanne: CHUV - Dr. med. Anna Surbone
- Lausanne: CPMA - Dr. med. Nicolas Vulliamoz
- Locarno: Centro Cantonale di Fertilità - Dr. med. Alessandro Santi
- Luzern: Kantonsspital Luzern - PD Dr. med. Alexandra Kohl Schwartz
- Luzern: Klinik St. Anna - Dr. med. Sabine Steimann
- Olten: Fertisuisse - PD Dr. med. Gideon Sartorius
- St. Gallen: Yuna - Dr. med. Vera Hungerbühler
- Winterthur: Admira, Winterthur - Dr. med. Monika Fähr
- Zürich: 360 Grad, Zürich - Dr. med. Florian Götze
- Zürich: GYN-A.R.T. AG - Dr. med. Moritz Suerdieck
- Zürich: OVA - IVF Clinic - Dr. med. Peter Fehr


Austria

- Graz: Medical University Graz - Dr. med. Marion Neumayer
- Innsbruck: Medical University of Innsbruck - PD Dr. med. Bettina Böttcher
- Linz: Johannes Kepler University Linz - PD Dr. med. Omar Josef Shebl
- Salzburg: Private Medical University, Salzburg - Dr. med. Katharina Winkler- Crepaz
- Wien: Medical University of Vienna - PD Dr. med. Julian Marschalek
- Wien: Saint Anna Children's Hospital – Univ.-Doz. Dr. med. Michael Dworzak

Supplementary Files


Figures

Algorithm for indicating fertility preserving therapies in females and males (adapted from von Wolff & Nawroth, 12).




The consortium of experts which control the project.

Figure 2



The internet platform FertiTOX which will be used to distribute the data.



Multimedia Appendixes

Supplement II: RedCap registry: Documentation in females before gonadotoxic.

URL: <http://asset.jmir.pub/assets/81b4ee38289e4f3c67e8ebe98353c251.pdf>

Supplement III: RedCap registry: Documentation in males before gonadotoxic therapy.

URL: <http://asset.jmir.pub/assets/59998b35794dc5c922967c9753480e46.pdf>

Supplement IV: RedCap registry: Documentation in females 12-15 months after the end of gonadotoxic therapy.

URL: <http://asset.jmir.pub/assets/971dca46a04cc5c593145cb147220c4b.pdf>

Supplement V: RedCap registry: Documentation in males 12-15 months after the end of gonadotoxic therapy.

URL: <http://asset.jmir.pub/assets/1b7160ec30f0a0557093b86bc6be1389.pdf>

